Opsynvi (Macitentan/Tadalafil) Patent Expiration, LOE Window & CMS Spending

Opsynvi (Macitentan/Tadalafil) by Johnson & Johnson: FDA Orange Book core substance LOE 2026-06-05 (last listed 2031-09-22), 0 AB generics, $30.1M 2024 CMS Part D & Medicaid spend, and $12,635 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN218490 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2026-06-05
Last Listed Patent or Exclusivity Date2031-09-22
Orange Book Patents (*PED Extensions)6 patents (3 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$30.1M
2024 Medicare Part D Spend$24.5M
2024 Medicaid Spend$5.6M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($12,635 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.